Inventor · disambiguated record
Matthew D. Correa
Also filed as: CORREA MATTHEW · CORREA MATTHEW D · CORREA MATTHEW DANIEL
27 granted patents·10 pending applications·141 citations·filing 2014–2024
96Inventor score
Top patents by PatentIndex Score
37 records- 0197US9499514B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2015·Granted Nov 22, 2016·28 cites·29 claims
- 0296US11634407B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Apr 25, 2023·5 cites·66 claims
- 0396US11185543B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2020·Granted Nov 30, 2021·5 cites·20 claims
- 0496US11149007B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Oct 19, 2021·14 cites·41 claims
- 0595US10357489B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Granted Jul 23, 2019·20 cites·26 claims
- 0694US11325889B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted May 10, 2022·11 cites·35 claims
- 0794US9808451B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2016·Granted Nov 7, 2017·12 cites·19 claims
- 0893US11873283B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 16, 2024·2 cites·34 claims
- 0993US11739075B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Aug 29, 2023·3 cites·17 claims
- 1093US11560371B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 24, 2023·3 cites·18 claims
- 1192US9968596B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2017·Granted May 15, 2018·8 cites·26 claims
- 1290US10227325B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2018·Granted Mar 12, 2019·6 cites·18 claims
- 1389US9556126B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Jan 31, 2017·10 cites·32 claims
- 1488US9938254B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2017·Granted Apr 10, 2018·5 cites·33 claims
- 1586US9156798B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Oct 13, 2015·5 cites·30 claims
- 1682US11358952B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Jun 14, 2022·1 cites·21 claims
- 1782US2024207255A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2024·Application pending·0 cites
- 1881US12404241B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 1980US2024217955A1Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 2079US9783505B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Oct 10, 2017·2 cites·29 claims
- 2179US2022387413A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 2278US10618883B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2019·Granted Apr 14, 2020·1 cites·15 claims
- 2378US2025188056A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 2477US12029738B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·23 claims
- 2577US11945804B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Granted Apr 2, 2024·0 cites·23 claims
- 2676US12103920B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Oct 1, 2024·0 cites·15 claims
- 2772US12227490B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Feb 18, 2025·0 cites·18 claims
- 2869US11365184B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2020·Granted Jun 21, 2022·0 cites·12 claims
- 2969US10675281B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2019·Granted Jun 9, 2020·0 cites·20 claims
- 3068US12486281B2Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Granted Dec 2, 2025·0 cites·25 claims
- 3168US2024287091A1Tricyclic quinolone bcl6 bifunctional degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3268US2025276981A1Tricyclic quinolone bcl6 bifunctional degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3364US2018221361A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Application pending·0 cites
- 3461US2025100995A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 3559US11306101B2Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2020·Granted Apr 19, 2022·0 cites·35 claims
- 3659US2024368118A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 3759US2024374591A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew D. Correa files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →